Invesco
ZVRA icon

Invesco’s Zevra Therapeutics ZVRA Stock Holding History

Invesco’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.79M Buy
264,389
+231,515
+704% +$2.57M ﹤0.01% 2333
2026
Q1 		$306K Buy
32,874
+692
+2% +$6.24K ﹤0.01% 3333
2025
Q4 		$288K Buy
32,182
+647
+2% +$6.12K ﹤0.01% 3398
2025
Q3 		$300K Buy
31,535
+11,791
+60% +$118K ﹤0.01% 3416
2025
Q2 		$174K Buy
19,744
+722
+4% +$5.86K ﹤0.01% 3550
2025
Q1 		$142K Buy
19,022
+638
+3% +$5.07K ﹤0.01% 3581
2024
Q4 		$153K Buy
18,384
+3,007
+20% +$25.7K ﹤0.01% 3562
2024
Q3 		$107K Sell
15,377
-255
-2% -$1.73K ﹤0.01% 3611
2024
Q2 		$76.6K Sell
15,632
-287
-2% -$1.36K ﹤0.01% 3782
2024
Q1 		$92.3K Sell
15,919
-585
-4% -$3.6K ﹤0.01% 3751
2023
Q4 		$108K Buy
16,504
+3,133
+23% +$14.7K ﹤0.01% 3677
2023
Q3 		$64.4K Hold
13,371
– – ﹤0.01% 3775
2023
Q2 		$68.2K Buy
+13,371
New +$72.1K ﹤0.01% 3787
2022
Q2 		– Sell
-10,208
Closed -$51K – 4162
2022
Q1 		$51K Buy
+10,208
New +$65K ﹤0.01% 3930
2021
Q4 		– Sell
-14,644
Closed -$136K – 4111
2021
Q3 		$136K Buy
14,644
+3,314
+29% +$33.4K ﹤0.01% 3887
2021
Q2 		$145K Buy
+11,330
New +$122K ﹤0.01% 3841

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco's ZVRA Position: Q2 2026 in Review

Invesco increased its Zevra Therapeutics (ZVRA) stake by 704% in Q2 2026, buying an estimated $2.57M and bringing the position to 264,389 shares worth $3.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

Invesco first reported a position in ZVRA in Q2 2021 and has held it in 16 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Invesco held 264,389 shares of Zevra Therapeutics worth $3.79M as of Q2 2026.
  • Invesco bought 231,515 Zevra Therapeutics shares in Q2 2026, an estimated $2.57M.
  • Zevra Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2333 holding.
  • Invesco first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.